MedTrace Logo

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

NCT00427336 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2011-10-27

Study results available
· View outcomes & findings →

Summary

Primary Objectives:

1. To determine the feasibility and toxicity of employing purine-analog based conditioning for allogeneic donor stem cell transplantation in patients with severe aplastic anemia (AA).
2. To determine the engraftment kinetics and degree of chimerism that can be achieved with this strategy.

Conditions

  • Aplastic Anemia

Interventions

DRUG

Fludarabine

30 mg/m\^2 by vein daily over 30 minutes

DRUG

Cyclophosphamide

300 mg/m\^2 by vein daily over 2 hours

DRUG

Antithymocyte Globulin

3.75 mg/kg by vein daily over 4 hours

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Paolo Anderlini, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-12-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427336 on ClinicalTrials.gov